Tags

Type your tag names separated by a space and hit enter

Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients.
J Clin Virol. 2004 Sep; 31(1):66-8.JC

Abstract

BACKGROUND

SARS-Cov is the etiologic agent of severe acute respiratory syndrome. An understanding of the antibody responses to the viral components is very important for diagnosis and vaccine development.

OBJECTIVE

The spectrum of SARS-specific antibody profiles in SARS patients was investigated from 7 to 210 days after the onset of the symptoms.

STUDY DESIGN

Serial serum samples from 14 SARS patients were isolated from 7 to 210 days after the onset of the symptoms, and were tested for anti-viral IgG and IgM by indirect immunofluorescence tests (IFA), anti-nucleocaspid antibody by ELISA tests and viral neutralization.

RESULTS

Anti-viral (IgG) and anti-nucleocaspid antibodies were observed in 13 of 14 patients at 14 days after the onset of symptoms, and in all 14 patients at 30-210 days thereafter. Anti-viral antibody (IgM) was detected maximally at 30 days, later than that for the IgG class. IgM antibody declined and became undetectable between 60 to 180 days after the onset of the symptoms. Neutralizing viral antibodies were demonstrated in the sera from all of the patients with SARS symptoms.

CONCLUSIONS

Anti-viral IgG, IgM, and anti-nucleocaspid antibodies were detected 7-30 days in patients after the onset of SARS symptoms. Anti-viral IgM antibodies disappeared earlier than IgG. Viral neutralization was demonstrated in the sera from the convalescent patients.

Links

PMC Free PDF

Authors+Show Affiliations

Shi Y
Department of Laboratory, General Hospital of Guangzhou, Military Command, 510010, China.
Wan Z
No affiliation info available
Li L
No affiliation info available
Li P
No affiliation info available
Li C
No affiliation info available
Ma Q
No affiliation info available
Cao C
No affiliation info available

MeSH

AdultAgedAntibodies, ViralEnzyme-Linked Immunosorbent AssayFluorescent Antibody Technique, IndirectHumansImmunoglobulin GImmunoglobulin MMiddle AgedNeutralization TestsNucleocapsidSevere acute respiratory syndrome-related coronavirusSevere Acute Respiratory SyndromeTime Factors

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15288616

Citation

Shi, Yulin, et al. "Antibody Responses Against SARS-coronavirus and Its Nucleocaspid in SARS Patients." Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, vol. 31, no. 1, 2004, pp. 66-8.
Shi Y, Wan Z, Li L, et al. Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. J Clin Virol. 2004;31(1):66-8.
Shi, Y., Wan, Z., Li, L., Li, P., Li, C., Ma, Q., & Cao, C. (2004). Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 31(1), 66-8.
Shi Y, et al. Antibody Responses Against SARS-coronavirus and Its Nucleocaspid in SARS Patients. J Clin Virol. 2004;31(1):66-8. PubMed PMID: 15288616.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. AU - Shi,Yulin, AU - Wan,Zhuoyue, AU - Li,Linhai, AU - Li,Ping, AU - Li,Chufang, AU - Ma,Qingjun, AU - Cao,Cheng, PY - 2004/05/12/revised PY - 2004/05/17/accepted PY - 2004/8/4/pubmed PY - 2005/2/16/medline PY - 2004/8/4/entrez SP - 66 EP - 8 JF - Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology JO - J Clin Virol VL - 31 IS - 1 N2 - BACKGROUND: SARS-Cov is the etiologic agent of severe acute respiratory syndrome. An understanding of the antibody responses to the viral components is very important for diagnosis and vaccine development. OBJECTIVE: The spectrum of SARS-specific antibody profiles in SARS patients was investigated from 7 to 210 days after the onset of the symptoms. STUDY DESIGN: Serial serum samples from 14 SARS patients were isolated from 7 to 210 days after the onset of the symptoms, and were tested for anti-viral IgG and IgM by indirect immunofluorescence tests (IFA), anti-nucleocaspid antibody by ELISA tests and viral neutralization. RESULTS: Anti-viral (IgG) and anti-nucleocaspid antibodies were observed in 13 of 14 patients at 14 days after the onset of symptoms, and in all 14 patients at 30-210 days thereafter. Anti-viral antibody (IgM) was detected maximally at 30 days, later than that for the IgG class. IgM antibody declined and became undetectable between 60 to 180 days after the onset of the symptoms. Neutralizing viral antibodies were demonstrated in the sera from all of the patients with SARS symptoms. CONCLUSIONS: Anti-viral IgG, IgM, and anti-nucleocaspid antibodies were detected 7-30 days in patients after the onset of SARS symptoms. Anti-viral IgM antibodies disappeared earlier than IgG. Viral neutralization was demonstrated in the sera from the convalescent patients. SN - 1386-6532 UR - https://www.unboundmedicine.com/medline/citation/15288616/Antibody_responses_against_SARS_coronavirus_and_its_nucleocaspid_in_SARS_patients_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓29 ↑6]

Related Citations

More